Top

Category: Pricing


Pricing, Regulations

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

January 17, 2023

Via: PMLiVE

The companies will now come under the alternative statutory scheme imposed by the government through law, demonstrating what the ABPI describes as ‘the depth of feeling that the current voluntary scheme is damaging the UK life sciences industry’. Introduced in […]


Pricing, Regulations

California sues insulin producers and PBMs over pricing

January 13, 2023

Via: Pharmaphorum

The lawsuit also takes aim at the three largest pharmacy benefit managers (PBMs) in the US – CVS Caremark, Express Scripts, and OptumRx – which are accused of adopting a system of rebates that incentivise manufacturers to raise list prices […]


Pricing, Regulations

Alzheimer’s drug Leqembi to launch at discount to Aduhelm

January 9, 2023

Via: Pharmaphorum

The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of disease who have confirmed presence of amyloid pathology. Eisai and […]


Pricing, Regulations

States Challenge Biden to Lower Drug Prices by Allowing Imports From Canada

December 14, 2022

Via: Kaiser Health News

The Biden administration is facing mounting pressure from states to let them import medicine from Canada to help lower prescription drug costs. Colorado on Dec. 5 became at least the fourth state to seek federal permission to use the strategy, […]


Pricing, Regulations

How eligible patient numbers affect price of rare disease drugs in France

December 7, 2022

Via: Pharmaphorum

Pricing and market access in France operate on a dual system, under which health technology assessments (HTAs) are conducted separately from pricing negotiations. The HTA body, the CT (Commission de la Transparence – Transparency Commission), is charged with providing guidance […]


Pricing, Regulations

Provention prices type 1 diabetes drug Tzield at $194,000

November 21, 2022

Via: Pharmaphorum

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the […]


Industry, Pricing, Regulations, Vaccines

Pfizer plans considerable 2023 Comirnaty markup

October 24, 2022

Via: Pharmaphorum

For over two years now, the US government has been running its public vaccination campaign – the largest in American history – and has purchased all of the Covid vaccines administered in the States, including over 500 million doses from […]


Pricing, Regulations

Amylyx ALS drug draws criticism over $158,000 price tag

October 3, 2022

Via: Pharmaphorum

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day set at a list price of $158,000 […]


Pricing, Regulations

Pharma prepares to continue fight as drug pricing bill passes House

August 15, 2022

Via: Biopharma Dive

The pharmaceutical industry is gearing up to minimize the effect of major drug legislation passed by Congress on Friday, the first time in many years lawmakers have overcome the drug lobby’s opposition to limits on their pricing power. On Friday, […]


Pricing, Regulations

Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations

July 25, 2022

Via: Kaiser Health News

A snappy political advertisement from the conservative advocacy group American Commitment bluntly charges Sen. Joe Manchin (D-W.Va.) with supporting a legislative plan that would drain “billions in funds” from Medicare. Specifically, the ad claims that Manchin and AARP, the well-known advocacy group for people […]


Industry, Pharma, Pricing, Regulations

Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe

July 22, 2022

Via: Pharmaphorum

The CMA delivered a preliminary judgment in the case last year which concluded that Pfizer and Flynn abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to balloon from around £2 million a year in 2012 to […]


Pricing, Regulations

‘Free’ Screening? Know Your Rights to Get No-Cost Care

July 6, 2022

Via: Kaiser Health News

An ounce of prevention … well, you know the rest. In medicine, prevention aims to spot problems before they worsen, affecting both a patient’s health and finances. One of the more popular parts of the Affordable Care Act, which allows […]


Pricing, Regulations

FDA Moves Forward with State Drug Import Plans

May 31, 2022

Via: Biopharm International

Despite a long history of difficulties in this area, FDA once again is taking steps to facilitate the import of less costly prescription drugs from Canada by states, Indian Tribes, and other entities. The Canadian government has objected to the […]


Pricing, Regulations

Insulin price caps on the horizon as Senate leader plans vote

March 23, 2022

Via: Pharmaphorum

Senate Majority Leader Chuck Schumer said yesterday that a vote on legislation which would introduce the cap – already backed in a House of Representatives vote last November – would take place this spring after the April recess. If passed, […]


Pricing, Regulations

How does rare disease prevalence impact drug pricing in England?

February 4, 2022

Via: Pharmaphorum

Decision makers in the healthcare industry including payers, especially those who rely on the use of cost-effectiveness analysis (CEA) to evaluate new drugs, are often criticised for failing to capture the holistic value of drugs in their health technology assessments […]


Pricing, Regulations

Biogen takes axe to Aduhelm price in a bid to drive take-up

December 20, 2021

Via: Pharmaphorum

The price reduction for Aduhelm (aducanumab) comes into play from 1 January and comes on the back of the “feedback of our stakeholders,” said the biotech’s chief executive Michel Vounatsos. “Too many patients are not being offered the choice of […]


Pricing, Regulations

Democrats agree last-ditch deal to save drug pricing plans

November 4, 2021

Via: Pharmaphorum

A new stripped back proposal has won over rebel Democrats whose earlier opposition led the plan to be shelved, despite being a longstanding pillar of Democrat policy and one of Joe Biden’s campaign pledges. Notable holdouts – including Senator Kyrsten […]


Pricing, Regulations

With D.C. drug pricing talks up in the air, the ‘endgame’ could still ‘have a bite,’ analyst says

October 6, 2021

Via: FiercePharma

With Democrats in Washington debating the specifics of the president’s infrastructure program, the pharmaceutical industry may be able to squeak out a much-desired drug pricing win. As the negotiations unfold, Politico reports that the party leadership may have to abandon […]


FDA, Pricing, Regulations

To lower drug prices, Senate leaders, FDA urge U.S. Patent and Trademark Office to alter patent processes

September 14, 2021

Via: FiercePharma

The Senate and the FDA are appealing to the U.S. Patent and Trademark Office (USPTO) to examine how it can limit the ability of pharmaceutical companies to leverage patent strategies to extend their drug monopolies. In separate letters last week […]


Pricing, Regulations

Biden Highlights Drug Pricing Reforms to Advance Legislative Agenda

August 13, 2021

Via: Biopharm International

The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden that supports several leading drug-price control policies strongly backed by Democrats. […]